2021 / 03

Next Paper
DOI: 10.47183/mes.2021.027

ORIGINAL RESEARCH

Isolation and characterization of Pseudomonas aeruginosa bacteriophages — potential agents for phage therapy

Kornienko MA, Kuptsov NS, Danilov DI, Gorodnichev RB, Malakhova MV, Bespiatykh DA, Veselovsky VA, Shitikov EA, Ilina EN
About authors

Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Maria A. Kornienko
Malaya Pirogovskaya, 1a, Moscow, 119435; moc.liamg@ayiramokneinrok

About paper

Funding: The study was supported by the State Assignment on the Development of a personalized approach to the therapy of infections using virulent bacteriophages (Code: Bacteriophage) (Russia).

Acknowledgments: the authors thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine, the Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical Biological Agency for their help with sequencing the genomes of bacteriophages.

Author contribution: Kornienko MA — study plan, data collection and processing, article authoring; Kuptsov NS — data collection and processing, article authoring; Danilov DI, Gorodnichev RB, Malakhova MV, Veselovsky VA — data collection; Bespiatykh DA — data processing, Shitikov EA — research plan, data processing, article authoring; Ilina EN — research plan, article authoring.

Compliance with ethical standards: the experiment was carried out in compliance with the Sanitary and Epidemiological Rules SP 1.3.2322-08 "Safe work with microorganisms of III–IV pathogenicity (hazardousness) groups and pathogens of parasitic diseases"; Sanitary and Epidemiological Rules SP 1.3.2518-09 "Amendments and additions #1 to the sanitary and epidemiological rules" Safe work with microorganisms of III–IV pathogenicity (hazardousness) groups and pathogens of parasitic diseases"; Sanitary and Epidemiological Rules SanPiN 2.1.7.2790-10 "Sanitary and epidemiological requirements for medical waste management"; Federal Clinical Recommendations "Rational use of bacteriophages in medical and anti-epidemic practice."

Received: 2021-07-19 Accepted: 2021-08-05 Published online: 2021-09-18
|
  1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnetet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018; 18 (3): 318–27.
  2. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, GómezZorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019; 32 (4).
  3. Kuzmenkov AY, Trushin IV, Vinogradova AG, Avramenko AA, Sukhorukova MV, Malhotra-Kumar S, et al. AMRmap: an interactive web platform for analysis of antimicrobial resistance surveillance data in Russia. Front Microbiol. 2021; 12: 620002.
  4. Pena C, Cabot G, Gómez-Zorrilla S, Zamorano L, OcampoSosa A, Murillas J, et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis. 2015; 60 (4): 539–48.
  5. 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization, 2021. Available from: https://www.who.int/publications/i/ item/9789240021303.
  6. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clinical Microbiology Reviews. 2019; 32 (2): e00066-18. DOI: 10.1128/CMR.00066-18.
  7. Akimkin VG, Darbeeva OS, Kolkov VF. Bakteriofagi: istoricheskie i sovremennye aspekty ih primenenija: opyt i perspektivy. Klinicheskaja praktika. 2010; 1 (4): 48–54. Russian.
  8. Chen F, Cheng X, Li J, Yuan X, Huang X, Lian M, et al. Novel lytic phages protect cells and mice against Pseudomonas aeruginosa infection. J Virol. 2021; 95 (8): e01832-20. DOI: 10.1128/ JVI.01832-20.
  9. Jault P, Cheng X, Li J, Yuan X, Huang X, Lian M, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019; 19 (1): 35–45.
  10. Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018; 10 (7): 351. DOI: 10.3390/v10070351.
  11. Kuptsov NS, Kornienko MA, Gorodnichev RB, Danilov DI, Malakhova MV, Parfenova TV, et al. Efficacy of commercial bacteriophage products against ESKAPE pathogens. Bulletin of RSMU. 2020; (3): 18–24.
  12. Mazzocco A, et al. Enumeration of bacteriophages using the small drop plaque assay system. Methods Mol Biol. 2009; 501: 81–85.
  13. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Pr. 1989, 2200 p.
  14. Seemann T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics. Oxford University Press. 2014; 30 (14): 2068–9.
  15. Aziz RK, et al. The RAST Server: Rapid annotations using subsystems technology. BMC Genomics. BioMed Central. 2008; 9: 75.
  16. Laslett D. ARAGORN, a program to detect tRNA genes and tmRNA genes in nucleotide sequences. Nucleic Acids Res. 2004; 32 (1): 11–16.
  17. Lefkowitz EJ, et al. Virus taxonomy: The database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res. 2018: 46 (1): 708–17.
  18. Meier-Kolthoff JP, Göker M. VICTOR: genome-based phylogeny and classification of prokaryotic viruses. Bioinformatics. 2017; 33 (21): 3396–404.
  19. Lefort V, Desper R, Gascuel O. FastME 2.0: A comprehensive, accurate, and fast distance-based phylogeny inference program. Mol Biol. 2015; 32 (10): 2798–800.
  20. FigTree. Available from: http://tree.bio.ed.ac.uk/software/figtree/. (Data obrashhenija: 16.07.2021).
  21. Enright MC, et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol. 2000; 38 (3): 1008–15.
  22. Alvi IA, et al. RLP, a bacteriophage of the family Podoviridae, rescues mice from bacteremia caused by multi-drug-resistant Pseudomonas aeruginosa. Arch Virol. 2020. 165 (6): 1289–97.
  23. Farlow J, et al. Complete Genome Sequences of 10 Phages Lytic against Multidrug-Resistant Pseudomonas aeruginosa. Microbiol Resour. 2020. 9: 29.
  24. Alvi IA, Asif M, Rehman S. A single dose of a virulent bacteriophage vB PaeP-SaPL, rescues bacteremic mice infected with multi drug resistant Pseudomonas aeruginosa. Virus Res. 2021; 292: 198250.
  25. Adnan M, et al. Isolation and characterization of bacteriophage to control multidrug-resistant Pseudomonas aeruginosa planktonic cells and biofilm. Biologicals. 2020; 63: 89–96.
  26. Treepong P, et al. Global emergence of the widespread Pseudomonas aeruginosa ST235 clone. Clin Microbiol Infect. 2018; 24 (3): 258–66.
  27. Principi N, Silvestri E, Esposito S. Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections. Front Pharmacol. 2019; 10: 513.
  28. Guo Y, Chen P, Lin Z, Wang T. Characterization of Two Pseudomonas aeruginosa Viruses vB_PaeM_SCUT-S1 and vB_PaeM_SCUT-S2. Viruses. 2019; 11 (4): 318. DOI: 10.3390/ v11040318.
  29. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, et al. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio. 2012; 3 (2): e00029-12. DOI: 10.1128/mBio.00029-12.
  30. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010; 201 (7): 1096–104.